Radiolabeled [3H]BPC-157 studies demonstrate that the peptide is finally metabolized into single amino acids, represented primarily by proline, in plasma, urine, and feces
If an underlying condition is responsible (liver disease, kidney disease, myeloproliferative disorder, or cancer), treating the underlying condition is the priority
The consistency of preclinical results and the plausible mechanisms give me reasonable confidence that the peptide does something meaningful biologically
Why Unsupervised Dosing Underdelivers The most common mistakes when dosing BPC-157 without guidance include: Wrong dose for bodyweight and condition
After one-third of the study participants have been enrolled and completed follow-up, the DSMBs will review the data and make recommendations concerning continuation, modification or termination of the study due to unexpectedly large beneficial effects or serious side effects and can suggest extension of the trial should the primary outcomes occur less often than anticipated
doi:10.1016/j.ejrad.2021.109722
